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Clinical Implications of Obesity With Specific Focus on
Cardiovascular Disease
A Statement for Professionals From the American Heart Association
Council on Nutrition, Physical Activity, and Metabolism
Endorsed by the American College of Cardiology Foundation
Samuel Klein, MD; Lora E. Burke, RN, MPH, PhD; George A. Bray, MD; Steven Blair, PED;
David B. Allison, PhD; Xavier Pi-Sunyer, MD; Yuling Hong, MD, PhD; Robert H. Eckel, MD
Abstract—Obesity adversely affects cardiac function, increases the risk factors for coronary heart disease, and is an
independent risk factor for cardiovascular disease. The risk of developing coronary heart disease is directly related to
the concomitant burden of obesity-related risk factors. Modest weight loss can improve diastolic function and affect the
entire cluster of coronary heart disease risk factors simultaneously. This statement from the American Heart Association
Council on Nutrition, Physical Activity, and Metabolism reviews the relationship between obesity and the cardiovas-
cular system, evaluates the effect of weight loss on coronary heart disease risk factors and coronary heart disease, and
provides practical weight management treatment guidelines for cardiovascular healthcare professionals. The data
demonstrate that weight loss and physical activity can prevent and treat obesity-related coronary heart disease risk
factors and should be considered a primary therapy for obese patients with cardiovascular disease. (Circulation. 2004;
110:2952-2967.)
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Obesity is an important risk factor for coronary heartdisease (CHD), ventricular dysfunction, congestive
heart failure, stroke, and cardiac arrhythmias. Weight loss in
obese patients can improve or prevent many of the obesity-
related risk factors for CHD (ie, insulin resistance and type 2
diabetes mellitus, dyslipidemia, hypertension, and inflamma-
tion)1,2 and can improve diastolic function.3 Therefore, it is
important for cardiovascular healthcare professionals to un-
derstand the clinical effects of weight loss and be able to
implement appropriate weight-management strategies in
obese patients. The purpose of this statement is to review the
physiological and cardiovascular effects of weight loss and
provide clinicians with appropriate treatment guidelines for
weight management in patients with obesity and cardiovas-
cular disease.
Clinical Effects of Weight Loss
Body Composition
The increase in body fat mass in most obese persons
represents primarily an increase in the size of fat cells,
although the number of fat cells may also be increased,
particularly in people with childhood-onset obesity.4 In addi-
tion, the specific distribution of excess fat can influence the
relationship between obesity and cardiac disease. Excess
abdominal adipose tissue, particularly visceral fat, and excess
triglyceride content in liver, skeletal muscle, and heart tissues
are associated with hepatic and skeletal muscle insulin
resistance, impaired ventricular function, and increased
CHD.5–9
Although an energy deficit of 3500 kcal is needed to
oxidize 1 lb of adipose tissue, a 3500-kcal energy deficit will
cause a1-lb loss in body weight because of the oxidation of
lean tissue and associated water losses. Approximately 75%
of weight lost by dieting is composed of fat and 25% is
fat-free mass (FFM).10 The addition of exercise training to a
diet program can decrease the percentage of weight lost as
FFM by half.10,11 Most, if not all, of the loss of fat results
from a decrease in the size (triglyceride content) of existing
fat cells,12 not a decrease in the number of fat cells.13 The
distribution of fat loss is heterogeneous, with greater relative
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losses of intraabdominal fat than total body fat mass, partic-
ularly in men and women with increased initial intraabdomi-
nal fat mass.14 In addition, diet-induced weight loss decreases
intramyocellular15 and intrahepatic16 lipids.
Clinical Outcomes
Intentional weight loss can improve or prevent many of the
obesity-related risk factors for CHD (ie, insulin resistance and
type 2 diabetes mellitus, dyslipidemia, hypertension, and
inflammation). Moreover, these metabolic benefits are often
found after only modest weight loss (5% of initial weight)
and continue to improve in a monotonic fashion with increas-
ing weight loss.17
Metabolic Syndrome
The metabolic syndrome represents a constellation of physi-
cal and metabolic abnormalities that are risk factors for
cardiovascular disease. The characteristics of this syndrome,
as defined by the National Cholesterol Education Program
(NCEP) Expert Panel on Detection, Evaluation, and Treat-
ment of High Blood Cholesterol in Adults (Adult Treatment
Panel III [ATP III]), include large waist circumference,
insulin-resistant glucose metabolism (impaired fasting glu-
cose, impaired glucose tolerance, and type 2 diabetes melli-
tus), dyslipidemia (high triglyceride and low serum HDL-C
[cholesterol] concentrations), and increased blood pressure.18
Patients who have the metabolic syndrome have a 1.5- to
3-fold increase in the risk of CHD and stroke.19–21 Weight
loss can improve all features of the metabolic syndrome.17
Insulin Resistance and Type 2 Diabetes Mellitus
Insulin sensitivity, with regard to glucose metabolism, im-
proves rapidly after beginning an energy-deficit diet before
much weight loss occurs and continues to improve with
continued weight loss.22 In patients with obesity and type 2
diabetes mellitus, a 5% weight loss at the end of 1 year of
dietary therapy can decrease fasting blood glucose, insulin,
hemoglobin A1c concentrations, and the dose of oral hypo-
glycemic therapy,23 whereas an average weight loss of30%
in extremely obese patients with diabetes after gastric bypass
surgery resulted in normalization of blood glucose and
glycosylated hemoglobin concentrations in 83% of patients.24
Weight loss can also prevent the development of new
diabetes in high-risk persons who are overweight or obese.25–28
Lifestyle dietary and activity modifications, which resulted in
modest (5%) weight loss, decreased the 4- to 6-year
cumulative incidence of diabetes by 50% in men and
women who were overweight or obese and had impaired
glucose tolerance.25,26 The Swedish Obese Subjects (SOS)
Study demonstrated that greater weight losses (16% of
body weight) induced by gastric surgery in patients who are
extremely obese (initial body mass index [BMI; weight in
kilograms divided by height in square meters] of 41 kg/m2)
were associated with a 5-fold decrease in the cumulative
incidence of diabetes for 8 years.27
Dyslipidemia
Weight loss decreases serum LDL-C and triglyceride concen-
trations, whereas increases in serum HDL-C typically are
seen when weight loss is sustained.1,29,30 The greatest relative
improvements in serum triglyceride and LDL-C usually occur
within the first 2 months of weight loss.31 The beneficial
effects on serum lipids are related to the percentage of weight
lost, and regaining the lost weight leads to a relapse in serum
concentrations. A sustained weight loss of 5% is needed to
maintain a decrease in serum triglyceride concentrations,
whereas serum total and LDL-C revert toward baseline if a
10% diet-induced weight loss is not maintained.31,32 In
contrast, data from the SOS study showed that an average
weight loss of 33% at 2 years after bariatric surgery decreased
serum triglyceride concentrations and increased serum
HDL-C concentrations, but it did not affect serum total
cholesterol.2
Hypertension
Weight loss decreases both systolic and diastolic blood
pressure in a dose-dependent fashion; therefore, greater
weight loss is generally associated with greater improvement
in blood pressure.33,34 Weight regain results in a steady
increase in blood pressure toward baseline. The results of
retrospective analyses of large surgical group experiences
showed that marked weight loss induced by gastric surgery
improved or completely resolved hypertension in 67% of
patients.35,36 In contrast, data from the SOS study revealed
that on average blood pressure began to progressively in-
crease 2 years after surgery.27 Most subjects enrolled in the
SOS study underwent vertical banded gastroplasty or gastric
banding procedures and lost less weight than those who
underwent gastric bypass. Subjects who had gastric bypass
surgery maintained a decrease in both systolic and diastolic
blood pressure for 5 years after surgery.37
Diet-induced weight loss can prevent the development of
hypertension in persons who are obese. The results from large
epidemiological studies and intervention trials suggest that
the risk of developing hypertension in normotensive women
is inversely correlated with changes in body weight.33,38 Data
from the SOS study showed, however, that the beneficial
effect of gastric surgery-induced weight loss in preventing
new cases of hypertension disappeared 3 years after surgery,
despite persistent weight loss.27
Pulmonary Disease
Obesity is associated with altered pulmonary function. A
marked excess in abdominal fat mass can mechanically
interfere with lung function because of the increased weight
on the chest wall and thoracic cage. In addition, obesity is
associated with serious pulmonary diseases, obstructive sleep
apnea (OSA), and obesity hypoventilation syndrome (OHS).
OSA is characterized by multiple episodes of apnea and
hypopnea during sleep caused by partial or complete upper
airway obstruction. The interruption in nighttime sleep and
hypoxemia causes daytime sleepiness and cardiopulmonary
dysfunction. Episodes of oxygen desaturation during apnea
and hypopnea cause transient increases in pulmonary artery
and pulmonary wedge pressures, and myocardial perfusion
defects.39 Over time, electrocardiographic abnormalities and
cardiac rhythm alterations, permanent pulmonary hyperten-
sion, right ventricle hypertrophy, and bilateral leg edema can
develop.40–42
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OHS is caused by a decreased ventilatory response to
hypercapnia, hypoxia, or hypercapnia and hypoxia and inad-
equate respiratory muscle strength to meet the increased
ventilatory demand caused by the mechanical effects of
obesity. Patients with OHS have shallow and inefficient
breathing, and a pCO2 50 mm Hg. Patients may become
more symptomatic when lying down because abdominal
pressure pushes up the diaphragm, which increases intratho-
racic pressure and reduces respiratory capacity. Pickwickian
syndrome is a severe form of OHS and is associated with
extreme obesity, irregular breathing, cyanosis, somnolence,
and right ventricular dysfunction.
Inflammation
Obesity is associated with an increase in circulating inflam-
matory markers, including C-reactive protein (CRP)43–45 and
cytokines (ie, interleukin-6 [IL-6], IL-18, and P-selec-
tin).46–49 Adipose tissue itself is a likely source of these
excess cytokines,46,50 and IL-6 stimulates the production of
CRP by the liver.51 The increase in inflammatory markers is
associated with insulin resistance52–56 and is an important
predictor of atherosclerotic events.57–61
Data from studies that have ranged in duration from 3
months to 2 years have revealed that weight reduction
decreases plasma CRP concentration.49,52,62–67 The decrease
in CRP is directly related to the amount of weight loss, fat
mass, and change in waist circumference. In one study, only
subjects who were insulin resistant experienced a weight
loss–induced decrease in CRP, an effect that paralleled
changes in insulin sensitivity.52 Plasma CRP concentrations
did not decrease and insulin sensitivity did not increase in
subjects who were insulin sensitive before weight reduction.
Decreases in plasma IL-6,48,49,65,67–69 IL-18,49,67 P-selectin,48
and tumor necrosis factor-48 concentrations have also been
reported66,68,69 after weight loss in subjects who are obese.
Autonomic Nervous System Dysfunction
Overweight and obesity are associated with cardiac auto-
nomic neuropathy. For example, a 10% increase in body
weight is associated with a decline in parasympathetic tone
and an increase in heart rate.70 Alterations in autonomic
nervous system function might be an important cause of
cardiovascular disease events and mortality, as suggested by
the relationship between heart rate and cardiovascular disease
mortality.71,72 Marked weight loss induced by bariatric sur-
gery increases vagal activity.73 In addition, weight loss
achieved by dieting also increases cardiac parasympathetic
activity,74–77 but this increase is not maintained in the absence
of sustained weight loss.77
Cardiovascular Disease
Although weight loss modifies many cardiovascular disease
(CVD) risk factors, it is not known whether weight reduction
decreases CVD events or CVD mortality in obese per-
sons.78–80 This important question has not yet been answered
because it is difficult to achieve prolonged periods of sus-
tained weight reduction (eg, 5 years) with nonsurgical
therapy81 and to perform prospective randomized controlled
trials (RCTs) involving bariatric surgery. Data from the SOS
study showed that despite a greater reduction in weight and
CVD risk factors after surgical than medical therapy for
obesity, no difference in cardiovascular disease events or
mortality was found at 10 years.82
Data from large population studies have revealed that
obesity is associated with increased CVD mortality.83–87
Moreover, CVD death rates are directly related to BMI in
both men and women. The risk of CVD mortality in obese
persons who have a BMI 35 kg/m2 was 2 to 3 times the risk
among lean persons (BMI 18.5 to 24.9 kg/m2),88 and a 30%
higher CHD mortality rate occurs for every 5-unit increment
of BMI.89 In addition, overweight in adolescence is associ-
ated with a 130% increased risk of CHD mortality in
adulthood.90
In general, data from large epidemiological studies have
shown that weight variability is associated with an increased
rate of CVD mortality.91 The interpretation of the results from
these studies is complicated because many studies assessed
weight variability rather than weight loss, included large
numbers of lean and mildly overweight subjects, and included
subjects who experienced “unintentional” weight loss, which
may have been caused by diseases that influence mortality.
Therefore, the available data are not adequate to reliably
determine whether intentional weight loss affects CVD mor-
tality, and carefully designed RCTs are needed to address this
issue.
Cardiovascular Structure and Function
Obesity, particularly severe obesity, is associated with abnor-
malities in cardiac structure and function.8,92 The severity of
these defects is associated with both the degree and duration
of obesity.93 Obesity is associated with an increase in total
blood volume and cardiac output and a decrease in peripheral
vascular resistance.8,94 In this setting, ventricular filling
pressures are elevated,95 which eventually results in increased
wall stress, diastolic dysfunction, and left ventricular hyper-
trophy.93,96,98 Abnormalities of the right heart can also occur
and may represent a combination of left heart disease,
recurrent pulmonary thromboemboli, and OSA or hypoven-
tilation or both.99 Finally, lipomatous deposition in the
interatrial septum has also been described100; however, this
anatomic alteration is unlikely to contribute to cardiac
dysfunction.
Weight loss, particularly in persons who are severely
obese, can improve cardiac structure and function.3,101 Im-
provements in fractional shortening are associated with de-
creases in hypertension and left ventricular internal dimen-
sion with reduced atrial and left ventricular free and septal
wall thickness. Moreover, improvements in left ventricular
diastolic filling and ejection fraction also occur.102 Improve-
ments in left ventricular mass occur in both normotensive and
hypertensive patients and are independent of the reduction in
blood pressure.103,104 In addition, adding exercise to a low-
calorie diet (LCD) may produce greater benefits in cardiac
structure105,106; however, these benefits are not consistent
across all studies.107,108 For example, substantial weight loss
(15% of baseline)108 and modest weight loss plus physical
training109 did not have beneficial cardiac effects in obese
adolescents. At present, the potential benefits of weight loss
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on cardiac function are not completely clear and require
further study.
Clinical Efficacy of Obesity Therapies
The goals of obesity therapy include decreasing body fat to
improve appearance, physical function, quality of life, and
medical health. Although surgical removal of large amounts
of subcutaneous adipose tissue (20% of total body fat mass)
can improve a person’s appearance, ability to ambulate, and
quality of life, it does not improve the metabolic CHD risk
factors associated with obesity110; it seems that fat loss
induced by negative energy balance is necessary to achieve
metabolic benefits. Current therapies available for weight
management that cause weight loss by inducing a negative
energy balance include dietary intervention, physical activity,
pharmacotherapy, and surgery. Behavior modification to
enhance dietary and activity compliance is an important
component of all of these treatments.
Dietary Intervention
Many different diets have been proposed for the treatment of
obesity. These dietary approaches vary in their total energy
prescription, macronutrient (fat, carbohydrate, and protein)
content, energy density, glycemic index, and portion control.
The energy content of a diet is the primary determinant of
weight loss. Very-low-calorie diets (VLCDs) provide 800
kcal/d, LCDs usually contain 800 to 1500 kcal/d, and a
balanced-deficit diet usually provides1500 kcal/d. An LCD
usually causes an 8% loss of body weight at 6 months of
treatment. The results from clinical trials may not reflect the
experience in clinical practice because these trials involved
subjects who volunteered for a weight loss study and often
included formal behavior modification as part of the study
protocol. The use of a VLCD usually produces a weight loss
of 15% to 20% within 4 months111–113; however, VLCDs
are associated with poorer weight loss maintenance and a
greater weight regain than are LCDs, so weight loss at 1 year
after treatment with a VLCD does not differ from treatment
with an LCD.113 In addition, treatment with a VLCD may be
particularly problematic for patients with CHD because of the
risk of diet-induced hypokalemia, dehydration, and
gallstones.
The macronutrient composition of a diet does not affect the
rate of weight loss unless macronutrient manipulation influ-
ences total energy intake or expenditure. The Expert Panel on
the Identification, Evaluation, and Treatment of Overweight
and Obesity in Adults convened by the National Institutes of
Health/National Heart, Lung, and Blood Institute recom-
mended a 500- to 1000-kcal/d deficit diet for obese persons,
which will initially result in a weekly weight loss of 1 to 2 lb
(0.45 to 0.9 kg). It is often difficult, however, to accurately
determine a patient’s daily energy requirements. Therefore,
calorie-intake guidelines for a weight-loss diet have been
suggested based on a patient’s initial body weight (Table
1).114 The calorie content of any prescribed diet must be
adjusted regularly, based on the patient’s weight-loss re-
sponse and treatment goals.
A low-fat diet is considered the standard approach for the
treatment of obesity.1 Data from diet intervention studies
support the notion that decreasing fat intake, even while
allowing ad libitum intake of carbohydrates and proteins,
causes a spontaneous decrease in total energy intake and
weight loss.115 In addition, a survey of obese persons who
were successful at maintaining long-term weight loss found
that they consumed 25% of calories from fats.116 However,
a recent systematic review of randomized controlled studies
that were specifically conducted to evaluate dietary therapy
for obesity found that weight loss induced by low-fat diets
and other weight-reducing diets were similar.117 The compos-
ite of these data suggests that low-fat diets can enhance
weight loss and may be particularly useful in selected
persons, but they are not necessarily more effective than
LCDs.
The use of low-carbohydrate diets has become increasingly
popular. Several RCTs compared the effect of low-
carbohydrate, high-protein, high-fat diets (eg, the Atkins diet)
with a conventional low-fat diet (30% energy from fats) in
adults118–123 or a very-low-fat diet (12% energy from fats)
in adolescents.124 In all studies, weight loss at 3 and 6 months
in subjects randomized to the low-carbohydrate diet was 2
times as great (4- to 5-kg greater weight loss) as those
randomized to the low-fat group. In 2 studies that observed
patients for 1 year, weight loss at 1 year was not significantly
different between groups, however.121,122 In general, these
studies also found the low-carbohydrate diet was more
beneficial in serum triglyceride and HDL-C concentrations as
compared with the low-fat diet, but the low-fat diet was more
beneficial in serum LDL-C concentration. Although these
changes in triglycerides and HDL-C after weight reduction on
low-carbohydrate diets appear favorable, it is not known
whether these alterations are associated with long-term ben-
eficial effects on CHD.125
The type of carbohydrate consumed also may be involved
in regulating energy intake, and a low glycemic index diet has
been proposed as a treatment for obesity. The glycemic index
refers to the increase in blood glucose that occurs after
consuming a fixed amount (usually 50 g) of available
carbohydrate from a test food relative to the increase in blood
glucose that occurs after consuming the same amount of
available carbohydrate from either glucose or white
bread.126,127 Most refined grain products and potatoes have a
high glycemic index, whereas most fruits, legumes, and
nonstarchy vegetables have a low glycemic index. The
glycemic response to a specific food that is ingested as part of
a meal can be altered by many factors, such as the method of
preparation and the effect of concomitantly ingested foods on
TABLE 1. Suggested Energy and Macronutrient Composition of
Initial Reduced-Calorie Diet
Body Weight, lb
Suggested Energy
Intake, kcal/d
150–199 1000
200–249 1200
250–299 1500
300–349 1800
350 2000
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intestinal motility. Data from a small (n14) randomized
controlled 1-year trial conducted in overweight adolescents
revealed that a reduced glycemic index diet resulted in a
greater decrease in body weight and BMI than did a reduced-
fat diet.128 The writing group is unaware of any RCTs
evaluating the effect of a low glycemic index diet on body
weight in adults.
The use of low-energy-density foods may be another
effective approach for treating obesity. The energy density of
a diet is defined as the calories present in a given weight of
food. A food’s energy density is directly correlated with its
fat content and inversely correlated with its water content.
Energy intake during a meal is partially regulated by the
weight of ingested food and is inversely correlated with
energy density.129 Moreover, the results of a 6-month RCT
demonstrated that providing subjects with ad libitum low-fat
and low-energy-density foods causes modest (1% to 2%)
weight loss.130
Portion control is an important aspect of reducing energy
intake. During ad libitum feeding, a direct relationship is
found between portion size served and intake; therefore,
increasing the size of the portion served increases the amount
of food consumed.131
Providing prepackaged prepared meals, either as frozen
entrees of mixed foods or liquid-formula meal replacements
improves portion control and can enhance weight loss. Data
from RCTs have shown that obese persons who were given
prepackaged prepared meals or liquid-formula meal replace-
ments lost several kilograms more weight than did those who
were randomized to a standard diet.132–134 Educating patients
about food labels, recipe modification, restaurant ordering,
social eating, and healthy cooking methods are also important
to help patients understand portion size and energy intake
during meals and snacks.
In summary, the data from RCTs demonstrate that different
dietary interventions can cause short-term weight loss. At the
present time, we suggest that patients who are overweight or
obese and trying to lose weight consume a diet that induces an
energy deficit of 500 to 1000 kcal/d and has a macronutrient
composition that is known to reduce the risk of CVD. This
diet involves (1) consuming a variety of fruits, vegetables,
grains, low-fat or nonfat dairy products, fish, legumes,
poultry, and lean meats; (2) limiting intake of foods that are
high in saturated fat, trans-fatty acids, and cholesterol; and
(3) following the current dietary guidelines of the American
Heart Association135 and the NCEP ATP III18 (Table 2).
These recommendations may require modification, based on
the results of ongoing and future dietary therapy studies. The
key to successful weight management is to provide patients
with a dietary regimen that results in long-term compliance.
The available data suggest that it is unlikely that one
approach is appropriate for all patients.
Physical Activity
Regular physical activity has important health benefits. A
consensus public health recommendation for physical activity
developed in the mid-1990s proposed that sedentary adults
should accumulate 30 minutes of at least moderate-
intensity physical activity (eg, brisk walking) on most but
preferably all days of the week.136–138 The health benefits of
30 minutes of daily moderate-intensity physical activity apply
to all persons. Data from several studies show that persons
who are overweight or obese and physically active (ie,
participate in 30 minutes of moderate-intensity physical
activity most days of the week) or who have moderate to high
levels of cardiorespiratory fitness (ie, in the upper four fifths
of the age and sex fitness distributions) have much lower
death rates from cardiovascular disease and all-cause mortal-
ity than people who are sedentary and unfit.87,139–143 There-
fore, regular physical activity may improve survival in
persons who are overweight or obese, independent of weight
loss.
Weight loss results from a negative energy balance, which
can be achieved by decreasing energy intake, increasing
energy expenditure, or both. It is usually much easier to
induce a daily energy deficit by restricting energy intake than
by increasing energy expenditure. The calories consumed
during physical activity can be estimated as a function of a
metabolic equivalent task (MET) score. One MET is the
energy consumed during resting conditions, such as television
viewing, and is equal to 1 kcal/kg of body weight per hour.
Other activities such as carrying packages, doing housework
or gardening (2 to 5 METs), walking at a pace of 3 to 4 mph
(3 to 4 METs), and jogging (8 to 10 METs) consume greater
amounts of energy. A person weighing 90 kg would need to
walk briskly for 4 to 5 h/d to increase his or her energy
expenditure above resting metabolic rate by an amount that is
equivalent to reducing energy intake by 750 to 1000 kcal/d.
Therefore, it is difficult to lose a substantial amount of weight
through physical activity. A review of 19 studies with
randomized designs showed that exercise plus diet caused a
0.1-kg/wk greater weight loss than did diet alone.144 Weight
loss induced by combining physical activity with diet de-
creases the loss of FFM that occurs when weight loss is
induced by diet alone.145
Data from observational studies strongly support the notion
that physical activity is critical for preventing weight re-
gain.145,146 Moreover, the available evidence suggests that a
high volume of physical activity, 80 to 90 minutes of
moderate-intensity activity such as walking or 35 minutes of
vigorous activity such as jogging, is necessary to maintain
weight loss.145 The interpretation of the results from these
TABLE 2. Suggested Dietary Nutrient Composition for
Patients Who Are Overweight or Obese
Nutrient Recommended Intake
Saturated fat1,2 7% of total calories
Monounsaturated fat 20% of total calories
Polyunsaturated fat 10% of total calories
Total fat 25% to 35% or less of total calories
Carbohydrate3 50% to 60% or more of total calories (complex
carbohydrates from a variety of vegetables, fruits,
whole grains)
Fiber 20–30 g/d
Protein 15% of total calories
Cholesterol 200 mg/d
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studies is complicated because subjects who achieved suc-
cessful long-term weight loss had chosen to be physically
active and had not been randomized a priori to a high-volume
physical activity program. Data from a recent prospective
RCT revealed that high-volume physical activity did not
completely prevent weight regain.147 Nonetheless, weight
regain after 6 months was smaller and total weight loss was
greater at 12 and 18 months in obese subjects who were
randomized to dietary and behavior therapy plus high-volume
physical activity (2500 kcal of energy expenditure per week)
than they were in persons randomized to dietary and behavior
therapy plus conventional physical activity (1000 kcal of
energy expenditure per week). Although it is in general
difficult to achieve long-term adherence to an exercise
program, several approaches have been used to enhance
adoption and maintenance of physical activity. Behavior-
intervention strategies originally developed for smoking ces-
sation or dietary programs have been used to increase
physical activity. One study showed comparable improve-
ments over 24 months in activity, fitness, and CHD risk
factors for participants who were randomly assigned to a
traditionally structured gymnasium-based program or to a
behaviorally based intervention.148 Increased contact by mail
or telephone also helps maintain long-term adherence to
exercise.149 Total exercise time during the course of a study is
greater when daily exercise is divided into multiple short
bouts (eg, 10-minute bouts 3 to 4 times per day) than one long
bout (eg, 30- to 40-minute bout once per day)150; ie, multiple
short bouts of exercise result in greater adherence to an
exercise program. In addition, many patients may be more
compliant with an exercise program conducted at home than
at a health club because fewer barriers are found with
home-based exercise, including costs and travel time. Devel-
oping a home-based walking program and using home exer-
cise equipment such as a treadmill has been shown to
improve exercise adherence and long-term weight loss.151,152
Finally, exercise does not need to be a structured activity.
Altering daily lifestyle activities (eg, walking instead of
riding, using stairs instead of escalators/elevators) may make
it easier to increase overall physical activity than would
participation in programmed exercise. In one study, weight
loss was similar after dietary therapy plus either lifestyle
activity or programmed exercise, but a trend toward better
maintenance of weight loss 1 year after treatment was
observed in individuals randomized to lifestyle activity than
to programmed exercise.153 Although these strategies are a
welcome improvement, all studies still report a decline in
exercise adherence over time.148,149,151,154
In summary, physical activity is not an effective approach
for achieving initial weight loss, but it does have beneficial
effects on fitness and obesity-related complications such as
CHD and diabetes. In addition, a high level of regular
physical activity is important for preventing and attenuating
weight regain after diet-induced weight loss. Most data
suggest that it is the total volume of physical activity that is
important to weight management and that it does not matter
whether the activity is of moderate or vigorous intensity, a
lifestyle or structured program, or taken in a single bout each
day or in several intermittent bouts.
Behavior Modification
Behavior therapy focuses on analyzing and modifying eating
and activity behaviors that increase body weight and provides
techniques to help patients change their lifestyle habits and
overcome barriers to compliance. A summary of behavioral
strategies for treating obesity is shown in Table 3. The most
important principles of behavioral treatment are that it (1) is
goal-oriented and specifies goals that can be easily attained
and measured, (2) is process-oriented and helps patients
develop realistic goals and a reasonable plan for reaching
those goals, and (3) involves making small rather than large
changes so that incremental steps are taken to achieve larger
and more distant goals.155,156
Self-monitoring, the systematic observation and recording
of target behaviors, is the cornerstone of behavioral treat-
ment.156 Self-monitoring tools include (1) food diaries in
which to record food intake, including types, amounts, energy
contents, and times, places, and feelings associated with
eating (usually in paper-and-pencil format but also available
on the Internet or in commercially available programs for use
on a personal digital assistant), (2) physical activity logs in
which to record the frequency, duration, and intensity of
exercise or step counters on which to monitor the daily steps
TABLE 3. Behavioral Strategies to Improve Weight Management
Strategy Description
Self-monitoring Record “what, where, and when” of eating and
physical activity to increase patients’
awareness of their own behavior.
Goal setting Set specific short-term targets in eating and
exercise habits to achieve incremental
improvements.
Stimulus control Identify triggers associated with poor eating
and physical activity behaviors, and design
strategies to break link.
Cognitive restructuring Change perceptions, thoughts, or beliefs
undermining weight control efforts, and help
patients develop realistic expectations about
weight loss.
Problem solving Analyze situations preventing maintenance of a
healthier lifestyle and identify possible solutions
to problems; maintain philosophy that planning,
not willpower, is key to weight management.
Relapse prevention Develop skills based on premise that lapses in
weight control behavior can be anticipated in
certain situations (eg, travel, celebrations, bad
mood).
Stress management Decrease psychological stress to prevent
dysfunctional eating.
Contingency management Use rewards (tangible or verbal) to increase
performance of specific behaviors or when
specified goals reached.
Social support Use assistance from family members and
friends in modifying lifestyle behaviors.
Ongoing contact Maintain visits, telephone calls, or Internet
communication with physician and office staff
or other healthcare professionals to promote
adherence with recommended lifestyle
changes.
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taken, and (3) weight scales on which to measure changes in
body weight. Self-monitoring increases patients’ awareness
of their behaviors, generates records that can be reviewed by
healthcare professionals, and provides targets for
intervention.
In clinical practice, formal behavior therapy can be pro-
vided through group sessions or individual meetings with a
healthcare professional who is skilled in the delivery of
behavioral techniques used to modify lifestyle habits.155,157 If
possible, contact should be regular, preferably once every 1 to
2 weeks, during the initial 6-month phase of a treatment
program.155 Comprehensive group behavior therapy, in con-
junction with diet and physical activity, usually results in an
9% body weight loss within 26 weeks of treatment (0.5
kg/week).157 Patients usually regain 33% of their lost
weight in the year after ending behavior therapy, but most
still maintain a weight loss of 5% at the end of 1 year.
Providing ongoing contact by scheduled visits, telephone
calls, food evaluation and exercise diaries, and Internet
communication can enhance long-term adherence and helps
prevent weight regain.158,159 In addition, Internet-based treat-
ment programs for weight loss160,161 and structured commer-
cial programs such as Weight Watchers162 can augment the
professional guidance provided by the physician.
Pharmacotherapy
Pharmacotherapy can help selected patients lose weight. The
approved indications for drug therapy for obesity are a BMI
30 kg/m2 or a BMI between 27 and 29.9 kg/m2 in conjunc-
tion with an obesity-related medical complication in patients
with no contraindications for therapy. Effective pharmaco-
therapy for obesity is likely to require long-term, if not
lifelong, treatment because patients who respond to drug
therapy usually regain weight when the therapy is stopped.
The expected length of drug treatment of obese patients who
respond to therapy makes it important to carefully consider
the long-term risks of being obese, the beneficial effects of
pharmacotherapy on body weight and obesity-associated
diseases, and the side effects and costs of treatment before
beginning therapy. In addition, pharmacotherapy alone is not
as effective as pharmacotherapy given in conjunction with a
comprehensive weight-management program.163 Therefore,
patients given drug treatment without the other standard
approaches to weight management, including behavior mod-
ification, diet education, and activity counseling, are exposed
to all of the risks of drug treatment without all of the medical
benefits.
Drug therapy adds a level of complexity to the treatment of
obesity. The patient with medication prescribed for obesity
may have comorbidities that already require pharmacother-
apy, thereby increasing the likelihood of nonadherence.164
Strategies to enhance medication compliance include regu-
larly assessing adherence and response to therapy, counseling
about and reinforcing the importance of adherence, simplify-
ing the treatment regimen, assisting the patient in reducing
barriers to adherence, providing reminders and cues to
facilitate improved adherence, and enlisting support when
needed.159,164 –166 In addition, weight loss drugs usually are
not covered by health insurance or health care plans, so a
considerable economic incentive exists for the obese
patient to discontinue taking these medications.
Medications for the treatment of obesity available in the
United States are listed in Table 4. Effective therapy for
obesity usually requires chronic intervention; however, only 2
drugs, sibutramine and orlistat, are approved for long-term
use.
Sibutramine
Pharmacology
Sibutramine is a -phenethylamine derivative that blocks
the reuptake of norepinephrine, sibutramine, and, to a lesser
degree, dopamine. Sibutramine decreases food intake by
producing early satiety during feeding and by delaying
initiation of the next meal. Although sibutramine has no
potential for abuse, it is classified as a Schedule IV drug.
Sibutramine is available in 5-, 10-, and 15-mg doses; 10 mg/d
as a single daily dose is the recommended starting level, with
titration up or down based on response. Doses 15 mg/d are
not recommended.
Clinical Efficacy
In a 1-year RCT, subjects treated with sibutramine lost 7%
of their initial body weight and those treated with placebo lost
2%. Of the subjects treated with sibutramine or placebo, 57%
and 20%, respectively, lost 5% of their initial body weight;
34% and 7%, respectively, lost 10% of their initial body
weight.167 Weight loss with intermittent sibutramine therapy
(15 mg/d given during weeks 1 through 12, 19 through 30,
and 37 through 48, and placebo given during the two 6-week
periods when sibutramine was withdrawn) was equivalent to
weight loss with continuous sibutramine therapy (15 mg/
d).168 Sibutramine therapy also has been shown to maintain
weight loss for 12 to 18 months in subjects who initially lost
weight by eating a VLCD163 or who successfully lost weight
after 6 months of sibutramine treatment.170 The use of
sibutramine in obese patients with either medication-
controlled hypertension171 or type 2 diabetes mellitus172
causes greater weight loss than with placebo therapy, but the
overall weight loss is less than that observed in studies
conducted in subjects who do not have comorbid disease.
Weight loss with sibutramine therapy is more effective
when combined with behavior and dietary therapies. In a
1-year RCT, weight loss with sibutramine therapy alone was
5 kg, with sibutramine therapy plus behavior modification
was 10 kg, and with sibutramine therapy plus behavior
modification and a structured meal plan was 15 kg.173
Side Effects and Safety
The most common side effects of sibutramine are dry
mouth, constipation, and insomnia. Sibutramine increases
TABLE 4. Drugs Approved by FDA for Treating Obesity
Generic Name
DEA
Schedule
Orlistat None
Sibutramine hydrochloride IV
Phentermine IV
Diethylpropion hydrochloride IV
Benzphetamine hydrochloride III
Phendimetrazine tartrate III
DEA indicates Drug Enforcement Agency.
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heart rate (a dose of 10 to 15 mg/d causes an increase in heart
rate of 4 to 6 bpm) usually in the first few weeks of treatment
and lasts as long as the drug is taken. Sibutramine also causes
a dose-related increase in blood pressure (a dose of 10 to 15
mg/d causes an average increase in systolic and diastolic
blood pressure of 2 to 4 mm Hg) and can prevent weight
loss–induced decrease in blood pressure.155 Therefore, careful
monitoring is needed when combining sibutramine with other
drugs that can increase blood pressure. Sibutramine should
not be used in patients who have uncontrolled hypertension,
a history of coronary artery disease, congestive heart failure,
cardiac arrhythmias, or stroke, or who are being treated with
monoamine oxidase inhibitors or selective serotonin reuptake
inhibitors.
CVD Risk Factors
The composite data from RCTs demonstrate that sibutra-
mine causes improvements in serum triglyceride, total cho-
lesterol, LDL-C, and HDL-C concentrations that are directly
related to the magnitude of the weight loss. However,
sibutramine therapy decreases or eliminates weight loss–
induced benefits on blood pressure.
Orlistat
Pharmacology
Orlistat blocks the digestion and absorption of dietary fat
by binding to intestinal lipases.174 The percentage of fat that
is malabsorbed is related to drug dose in a curvilinear
fashion.175 Near-maximal fat malabsorption occurs at a dose
of 120 mg when given with a meal, which causes malabsorp-
tion of30% of fat ingested from a meal that contains30%
of energy as fat. Less than 1% of ingested orlistat is absorbed;
therefore, it has no effect on systemic lipases.176
Clinical Efficacy
The effects of orlistat on body weight and CHD risk factors
have been evaluated in a large number of RCTs. The data
from most studies demonstrate that at 1 year, subjects who
were randomized to orlistat therapy (120 mg tid) lost 8% to
10% of their initial body weight and those randomized to
placebo therapy lost 4% to 6%.177–181 Approximately 33%
more patients treated with orlistat lost 5% of their body
weight than did those treated with placebo;2 times as many
patients treated with orlistat lost 10% of their body weight
as did those treated with placebo. Ending orlistat therapy
results in weight regain,177,180 and starting orlistat therapy
after successful diet-induced weight loss helps maintain body
weight.182 In subjects with obesity and type 2 diabetes
mellitus who are treated with sulfonylureas,183 metformin,184
or insulin,185 the percentage who achieve a 5% or 10%
reduction in body weight is 2 to 3 times higher in those
receiving orlistat plus dietary therapy than it is in those
receiving dietary therapy alone. The overall weight loss effect
of orlistat therapy in patients with diabetes is less than that
reported in previous studies of obese patients who did not
have diabetes, however.
Recently, the results of a 4-year RCT were reported.28 The
lowest body weight was achieved during the first year and
was greater in the orlistat-treated group (11% weight loss)
than in the placebo-treated group (6% weight loss). Subjects
regained weight during the remainder of the trial; orlistat-
treated subjects had lost 6.9% of their initial body weight and
placebo-treated subjects had lost 4.1% at the end of 4 years.
Orlistat therapy also decreased the cumulative 4-year inci-
dence of type 2 diabetes mellitus by 37%.
Side Effects and Safety
About 70% to 80% of subjects treated with orlistat
experienced 1 gastrointestinal event as compared with
50% to 60% of those treated with placebo. Gastrointes-
tinal events usually occurred early (within the first 4
weeks), were of mild or moderate intensity, were usually
limited to 1 or 2 episodes, and resolved despite continued
orlistat treatment. Approximately 4% of subjects treated
with orlistat and 1% of subjects treated with placebo
withdrew from the studies because of gastrointestinal
complaints. During treatment, small decreases in plasma
fat-soluble vitamins, particularly vitamins A, D, and E, can
occur, although plasma concentrations almost always re-
main within the reference range. A few patients, however,
may experience decreases in plasma vitamin concentra-
tions to below the reference range. Because it is impossible
to determine a priori which patients will need vitamin
supplements, it is recommended that all patients who are
treated with orlistat be given a daily multivitamin supple-
ment that is taken at a time when orlistat is not being
ingested.
Orlistat can have medically significant effects on the
absorption of lipophilic medications if both drugs are taken
simultaneously. Subtherapeutic plasma cyclosporin levels
that occurred in organ transplant recipients after they began
orlistat therapy for obesity have been reported.186–189 There-
fore, orlistat should not be taken for 2 hours before or after
the ingestion of lipophilic drugs, and plasma drug concentra-
tions should be followed to ensure appropriate dosing. Or-
listat does not affect the absorption of selected drugs with a
narrow therapeutic index (warfarin, digoxin, phenytoin) and
selected drugs that are likely to be taken concomitantly with
orlistat (glyburide, oral contraceptives, furosemide, captopril,
nifedipine, and atenolol).189
CVD Risk Factors
Because of its weight loss effects, orlistat therapy
improves all major cardiovascular disease risk factors such
as blood pressure and insulin sensitivity. Moreover, data
from several RCTs suggest that orlistat has a beneficial
effect on serum cholesterol concentrations that is indepen-
dent of weight loss alone. Subjects given orlistat had a
greater reduction in serum LDL-C concentrations than
those given placebo, even after adjusting for percentage of
weight loss.178,179 The mechanism responsible for this
additional lipid-lowering effect may be related to the effect
of orlistat in blocking both dietary cholesterol and triglyc-
eride absorption.190 In contrast, orlistat is not as effective
in lowering serum triglyceride concentrations, presumably
because it increases the proportion of absorbed energy
derived from carbohydrate, which tends to increase serum
triglycerides.191
Phentermine
Phentermine is a -phenethylamine derivative that stimu-
lates the release of norepinephrine and dopamine from
nerve terminals. Although phentermine is not approved by
the Food and Drug Administration (FDA) for long-term
use, it is the most commonly prescribed anorexiant medi-
cation in the United States,192 presumably because it is less
expensive than sibutramine. Phentermine was approved by
the FDA 30 years ago, when the criteria needed for
approval were less rigorous than they are currently. There-
fore, fewer studies have evaluated the efficacy and safety
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of phentermine therapy than have evaluated sibutramine
and orlistat. Only one long-term (36 weeks) RCT evaluated
the effect of phentermine therapy on body weight.193 In
that study, obese women were randomized to dietary
therapy and treatment with daily phentermine, daily phen-
termine every other month alternating with daily placebo
every other month, or daily placebo. Of the 108 enrolled
subjects, approximately two thirds completed the study;
among those who completed the study, the groups that
received either continuous or intermittent phentermine
therapy lost 13% of their initial weight as compared with
a 5% weight loss in the placebo group.
Side Effects and Safety
The most common side effects of phentermine are dry
mouth, insomnia, and constipation. Although all sympatho-
mimetic agents can increase blood pressure and heart rate,
these side effects are uncommon when weight loss is
adequate.
Herbal Products
Several different dietary supplements and herbal preparations
have been used to treat obesity, including chromium picoli-
nate, garcinia cambogia as a source of hydroxycitrate, chi-
tosan that is claimed to reduce fat absorption, phenylephrine
from Citrus aurantium (bitter orange), and ma huang as a
source of ephedra alkaloids with or without guarana as a
source of caffeine. In general, few RCTs have evaluated the
clinical efficacy of these agents, and most of the RCTs that
have been done were of substandard quality194–196; however,
data from several RCTs demonstrated greater weight loss in
subjects given herbal products that contain ephedra than in
those given placebo.197,198 Nonetheless, the sale of ephedra in
over-the-counter products was recently banned by the FDA
because of concerns about serious adverse cardiovascular
effects.
Bariatric Surgery
Bariatric surgery is the most effective therapy available for
people who are extremely obese. The current indications for
surgical therapy were established at a consensus conference
held at the National Institutes of Health in 1991.199 The panel
recommended that bariatric surgery be considered for obese
persons who have a BMI of 35.0 to 39.9 kg/m2 plus 1
severe obesity-related medical complication such as hyper-
tension, type 2 diabetes mellitus, heart failure, or OSA and
persons with a BMI 40 kg/m2. At present, 109 000
bariatric surgery procedures are performed each year in the
United States.
Five surgical procedures are most commonly used to
treat obesity: (1) gastric bypass (Roux-en-Y anastomosis),
(2) gastroplasty (gastric stapling, vertical banded gastro-
plasty, silastic ring gastroplasty), (3) gastric banding
(LAP-BAND), (4) biliopancreatic diversion (partial bilio-
pancreatic bypass), and (5) biliopancreatic diversion with
duodenal switch (partial biliopancreatic bypass with duo-
denal switch). Gastric bypass accounts for 70% of the
bariatric operations performed in the United States. This
procedure involves the construction of a small (20 mL)
proximal gastric pouch, which empties into a segment of
jejunum that is anastomosed to the pouch as a Roux-en-Y
limb. Gastroplasty involves the formation of a small pouch
along the lesser curvature near the gastroesophageal junc-
tion, which empties into the rest of the stomach through a
1-cm outlet stoma. Gastric banding involves the placement
of a band around the upper stomach. The band circumfer-
ence size can be changed by percutaneously inflating or
deflating a balloon in the band that is connected to a
subcutaneous port and is commonly adjusted after surgery
based on weight loss response and gastrointestinal symp-
toms. Biliopancreatic diversion involves the creation of a
200- to 500-mL proximal gastric pouch and transsection of
the small intestine 250 cm from the ileocecal valve; the distal
end of the small intestine is anastomosed to the gastric pouch
and the proximal limb anastomosed to the ileum 50 cm from the
ileocecal valve. These anastomoses create a 200-cm “alimentary
tract,” a variable length (300 to 500 cm) “biliary tract,” and a
50-cm “common tract” in which digestion and absorption of
ingested food occur. The biliopancreatic diversion with duode-
nal switch procedure involves the removal of 60% of the
greater curvature of the stomach and transection of the proximal
duodenum. The proximal portion of the duodenum is anasto-
mosed end-to-end to the distal small intestine 250 cm proximal
to the ileocecal valve. The distal end of the resected proximal
intestine, which receives secreted pancreatic enzymes, is anas-
tomosed to the ileum 100 cm proximal to the ileocecal valve. All
bariatric surgical procedures have been performed as open and
laparoscopic procedures.
The approximate weight loss reported after each procedure
is shown in Table 5.114 It is difficult to determine the relative
weight loss effectiveness of each procedure because only
vertical banded gastroplasty and gastric bypass have been
compared directly in RCTs.200–203 The data from these RCTs
consistently revealed that weight loss was greater with the
gastric bypass procedure than with vertical banded gastro-
plasty. Fewer studies have evaluated the long-term effects of
gastric banding, biliopancreatic diversion, and biliopancreatic
diversion with duodenal switch than gastric bypass or gastro-
plasty because the procedure has been more recently devel-
oped or has been performed less often.
The perioperative mortality rate within 30 days after
open bariatric surgery is 1%23,200,204,205 but can vary
depending on the experience of the surgeon.206 Approxi-
mately 75% of deaths are caused by anastomotic leaks and
peritonitis and 25% by pulmonary embolism. Laparoscopic
gastric bypass is associated with fewer wound complica-
TABLE 5. Effect of Different Bariatric Surgical Procedures on
Long-Term (>2 y) Body Weight
Procedure
Approximate
Loss of Initial
Weight, %
Approximate
Loss of Excess
Weight, %
Gastric banding 20–35 35–70
Gastroplasty 20–25 40–50
Gastric bypass 25–30 50–65
Biliopancreatic diversion 
duodenal switch
35–40 70–80
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tions, less postoperative pain, less blood loss, and shorter
hospital stays and convalescence periods than does the
open procedure207; however, late anastomotic strictures
occur more frequently after the laparoscopic than after the
open procedure.
Treatment Guidelines
The goal of weight loss therapy for patients with CVD is to
reduce or eliminate CHD risk factors and improve cardiac
function. Aggressive weight loss therapy could be harmful in
selected patients, such as those who have had a recent
myocardial infarction or stroke or who have unstable angina,
and attempts at weight loss should be delayed until these
patients are medically stable.
Clinical Evaluation
The physician’s office should be an environment that is
sensitive to the needs of obese patients. The waiting room
should contain chairs without arms, large gowns and large
blood pressure cuffs should be available, and a scale that can
weigh patients who weigh 300 lb should be available and
located in a private area. The initial assessment should
include an appropriate history, physical examination, and
laboratory tests.
History
In addition to a standard medical interview, a patient’s
history should include an assessment of (1) weight history
(highest and lowest adult body weight, previous weight
loss attempts, weight pattern, and potential triggers and
social and environmental factors that contributed to weight
gain), (2) dietary history, including an assessment of types
and timing of meals and snacks and an attempt to identify
possible triggers that result in excessive energy intake, (3)
physical activity and function (daily and exercise activi-
ties, physical limitations, effect of obesity on physical
lifestyle), (4) obesity-related health risk (age of onset and
duration of obesity, family history of obesity and obesity-
related medical complications, current obesity-related dis-
ease), (5) possible psychiatric illnesses, such as binge
eating disorder and depression, that may require therapy
before a weight loss program is initiated, and (6) ability to
lose weight (desire to lose weight, weight loss goals and
expectations, limitations for achieving weight loss, includ-
ing medications and illnesses, lifestyle and work patterns,
financial resources, and special needs).
Physical Examination
The patient’s BMI and waist circumference should be
determined. BMI is generally correlated with percentage of
body fat in a curvilinear fashion.208 Some people with an
“obese” BMI, who have a normal amount of body fat and
a large muscle mass, are not at increased risk for CHD,
whereas people with a “normal” BMI, who have excessive
body fat and small muscle mass, are at increased risk.
Waist circumference, measured halfway between the last
rib and the iliac crest, correlates with abdominal fat mass.5
Table 6 provides a classification of risk based on BMI. A
waist circumference of 88 cm (35 in) for women and
102 cm (40 in) for men is associated with an increased
risk of metabolic diseases and CHD.1 Additional assess-
ments should include measuring blood pressure with a
large cuff and searching for physical signs of right or left
ventricular dysfunction, congestive heart failure, and pul-
monary disease. An electronic stethoscope can increase a
physician’s ability to detect cardiac abnormalities in pa-
tients who are extremely obese.
Laboratory Tests
An ECG is needed to check for evidence of CHD and to
obtain a baseline tracing for future comparisons. Standard
blood tests should be performed to search for CHD risk
factors, including prediabetes (impaired fasting blood
glucose or impaired glucose tolerance), dyslipidemia (in-
creased triglycerides, low HDL-C, and increased LDL-C),
and the metabolic syndrome. Additional studies may be
needed to further evaluate specific clinical suspicions
based on the history and physical examination, such as
TABLE 6. Weight Classification by BMI*
Obesity Class BMI, kg/m2 Disease Risk
Underweight 18.5 Increased
Normal 18.5–24.9 Normal
Overweight 25.0–29.9 Increased
Obesity I 30.0–34.9 High
II 35.0–39.9 Very high
Extreme Obesity III 40.0 Extremely high
*Data from Obes Res.1
Additional adiposity-related risk factors: waist circumference 40 (in men)
and 35 (in women); weight gain of 5 kg since age 18–20 y.
TABLE 7. Weight Loss Treatment Guidelines*
BMI Category, kg/m2
Treatment 25.0–26.9 27.0–29.9 30.0–34.9 35.0–39.9 40.0
Diet, physical activity, behavior therapy, or all 3 Yes Yes Yes Yes Yes
Pharmacotherapy† With obesity-related disease Yes Yes Yes
Surgery‡ With obesity-related disease Yes
*Data from Obes Res.1
†Pharmacotherapy should be considered only in patients who are not able to achieve adequate weight loss by available conventional lifestyle modifications and
who have no absolute contraindications for drug therapy.
‡Bariatric surgery should be considered only in patients who are unable to lose weight with available conventional therapy and who have no absolute
contraindications for surgery.
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sleep studies to diagnose OHS or OSA and an exercise
treadmill test or electron beam computerized tomography
scanning or both to evaluate CHD risk. The comparative
value of exercise tolerance testing and electron beam
computerized tomography in obese subjects has not been
determined. Exercise treadmill testing is not recommended
for patients without cardiac symptoms, and neither exer-
cise treadmill testing nor electron beam computerized
tomography scanning should be performed in patients who
are at low risk for CHD, based on clinical judgment or
Framingham risk score.209 –211
Therapeutic Options
Appropriate management requires identifying patients who
need treatment, developing a realistic treatment plan, and
implementing a defined treatment strategy that can be
modified as needed during long-term surveillance. The
Practical Guide to the Identification, Evaluation, and
Treatment of Overweight and Obesity in Adults was
developed by the North American Association for the
Study of Obesity in conjunction with the National Heart,
Lung, and Blood Institute.212 Suggested guidelines from
the guide for selecting among different weight loss treat-
ment options, based on disease risk, are shown in Table 7.
A typical clinical consultation involves a physician’s
giving advice without adequate consideration of the pa-
tient’s priorities, motivation, or confidence in undertaking
change.213 In contrast, obesity therapy should involve
“patient-centered counseling,” which encourages patients
to set goals and express their own ideas for therapy, with
input from the healthcare professional. The treatment plan
also must take into account the patient’s readiness for
therapy and the patient’s ability to comply with the
proposed treatment plan. Realistic goals should be estab-
lished and frequent follow-up visits should be scheduled to
monitor progress, modify the treatment plan as needed, and
provide encouragement. Effective therapy requires a long-
term structured approach with continued support from the
physician and other caregivers, particularly during periods
of patient recidivism and weight regain.
Reducing energy intake is the cornerstone of weight
management therapy. Providing appropriate nutrition
counseling and the behavior modification therapy needed
to implement dietary changes within the setting of a busy
outpatient practice is difficult if not impossible for most
physicians because they do not have the time or expertise
to provide this kind of care. Therefore, referral to a
reputable weight loss program or experienced dietitian
should be considered, if these resources are available.
Additional therapy with weight loss medications or bari-
atric surgery can be useful in properly selected patients.
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